Recommendations

Document Overview

Design and created by Guideline Central in participation with the Hidradenitis Suppurativa Foundation.

Hidradenitis Suppurativa - Topical, Intralesional, and Systemic Medical Management

Hidradenitis Suppurativa Foundation

Publication Date: Jul 1, 2019

Page Last Updated: May 6, 2026

ASCCP Grading System

Strength of recommendation
A	Good evidence for efficacy and substantial clinical benefit support recommendation for use.
B	Moderate evidence for efficacy or only limited clinical benefit supports recommendation for use.
C	Evidence for efficacy is insufficient to support a recommendation for or against use, but recommendations may be made on other grounds.
D	Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use.
E	Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use.

Document Overview

Document Title: Hidradenitis Suppurativa - Topical, Intralesional, and Systemic Medical Management

Authoring Society: Hidradenitis Suppurativa Foundation

Document Publication Date: Jul 1, 2019

Page Last Reviewed/Updated: May 6, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: www.jaad.org/article/S0190-9622(19)30368-8/fulltext

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Scope: Management, Treatment

Diseases/Conditions (MeSH)

D017497 - Hidradenitis Suppurativa

Keywords: Hidradenitis suppurativa, Nd:YAG, carbon dioxide laser, clindamycin, ertapenem, finasteride, keratolytic agents, laser, microbiome, oral contraceptive pills, retinoids, rifampin, spironolactone

Inclusion Criteria: Female, Adolescent, Child

Health Care Settings: Ambulatory, Childcare Center

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Number of Source Documents: 120

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: No

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No

Quality of evidence
I	Evidence from at least one randomized, controlled trial.
II	Evidence from at least one clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), or from multiple time-series studies, or dramatic results from uncontrolled experiments.
III	Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.

Hidradenitis Suppurativa - Topical, Intralesional, and Systemic Medical Management

Recommendations

Topical and Intralesional Therapies

Systemic Antibiotics

Hormonal Agents

Retinoids

Immunosuppressants

Biologics

Pediatric and Pregnant Patients

ASCCP Grading System

Document Overview

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Recommendation Development Processes & Methodology